Are Analysts Bullish Neovasc Inc. (NASDAQ:NVCN) After Last Week?

May 14, 2018 - By Darrin Black

Neovasc Inc. (NASDAQ:NVCN) Logo

Neovasc Inc. (NASDAQ:NVCN) Ratings Coverage

Among 2 analysts covering Neovasc Inc (NASDAQ:NVCN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neovasc Inc had 3 analyst reports since January 19, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, March 29 by Leerink Swann. On Thursday, March 29 the stock rating was maintained by Canaccord Genuity with “Buy”. Below is a list of Neovasc Inc. (NASDAQ:NVCN) latest ratings and price target changes.

29/03/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $1.05 New Target: $0.5 Maintain
29/03/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $5 New Target: $2 Maintain
19/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $1.05

The stock decreased 1.02% or $0.0004 during the last trading session, reaching $0.0387. About 29.85M shares traded. Neovasc Inc. (NASDAQ:NVCN) has declined 92.17% since May 14, 2017 and is downtrending. It has underperformed by 103.72% the S&P500.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $68.45 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It currently has negative earnings. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

Another recent and important Neovasc Inc. (NASDAQ:NVCN) news was published by which published an article titled: “Neovasc’s (NVCN) CEO Fred Colen on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

WP Twitter Auto Publish Powered By :